Intercell reports Phase II Study Results of its Vaccine Enhancement Patch for Pandemic Influenza

Vienna (Austria)/Gaithersburg (USA), July 2, 2010 – Intercell AG (VSE: ICLL) today
announced the results of a Phase II clinical trial of its investigational Vaccine Enhancement
Patch (VEP) system for avian H5N1 influenza. In this development program, Intercell is
working under a contract with the U.S. Department of Health and Human Services (HHS) to
develop a dose‐sparing approach with potential for a single dose immunization against
pandemic influenza that combines a H5N1 vaccine with Intercell’s LT adjuvant patch.
Following encouraging pre‐clinical and clinical Phase I proof‐of‐concept trials conducted
under this HHS contract, the clinical Phase II study was designed to determine the safety and
the optimal combination/dose of an injectable H5N1 influenza vaccine (30 and 45μg antigen)
and Intercell’s VEP (50 and 100μg LT adjuvant) applied at the injection site. A total of 500
healthy adults were recruited in 6 study groups.
The study did not identify the optimal combination of antigen and adjuvant because no
statistically significant difference in seroprotection rates as measured by Haemagglutinin
Inhibition (HI) assay was observed when comparing groups with and without VEP.
However, the study results demonstrated a good safety profile for all doses of injectable
vaccine and adjuvant patches studied. Furthermore, a dose‐dependent response to the H5N1
antigen was observed. Anti‐LT IgG titers in study subjects receiving the patch confirmed that
Intercell’s VEP could consistently deliver the vaccine adjuvant.
Intercell intends to conduct further clinical evaluation using its VEP in combination with an
injectable H5N1 vaccine to be supplied by GlaxoSmithKline (GSK) as part of a collaborative
agreement signed in December 2009.
HHS and Intercell are currently considering the next steps for this development program.
ʺSingle‐dose protection against highly pathogenic pandemic influenza strains such as H5N1 is
an important goal for pandemic protection, but one which has been shown to be challenging ”,
said Thomas Lingelbach, Chief Operating Officer of Intercell and CEO & President Intercell
USA Inc. “We think that despite the inconclusive results, our Vaccine Enhancement Patch is
uniquely positioned to have the potential to achieve single‐dose protection and hence Intercell
using its partner GSK’s vaccine intend to proceed with further clinical evaluation.”
About Pandemic Influenza
Three influenza pandemics occurred in the 20th century leading to the death of more than 50
million people globally, and the current H1N1 pandemic influenza is a reminder of the
ongoing reality of such threats to public health. By U.S. government estimates, pandemic
influenza has a greater potential to cause deaths and illnesses than virtually any other natural
health threat. Signs of a pandemic influenza have emerged in Southeast Asia, as lethal
infections of poultry and humans with H5N1 avian influenza virus continue. This H5N1 virus
is now endemic in bird populations, having spread to more than 40 countries and causing the
deaths of hundreds of millions of birds. Furthermore, the World Health Organization reports
that the number of avian influenza cases in humans has reached more than 370 cases in 14
countries.

About the HHS Pandemic Influenza activities
Under the HHS Pandemic Influenza Plan of November 2005, key goals for vaccine
preparedness are to stockpile enough pre‐Pandemic Influenza vaccines to cover 20 million
people in the critical workforce and to develop sufficient domestic manufacturing capacity to
produce pandemic vaccine for the entire U.S. population of 300 million within 6 months of
pandemic onset.
About Intercell’s Vaccine Enhancement Patch
Intercell believes that its Vaccine Enhancement Patch has the potential for the development of
improved influenza vaccines, especially in the field of pandemic influenza. Pre‐clinical studies
and clinical trial results using the Vaccine Enhancement Patch with H5N1 vaccine suggest that
this strategy may be used for other applications where improved immunogenicity, decreased
antigen doses, or fewer immunization visits are desired.

About Intercell AG
Intercell AG is an innovative biotechnology company that develops novel vaccines for the
prevention and treatment of infectious diseases with substantial unmet medical needs.
Intercellʹs vaccine to prevent Japanese Encephalitis is the Companyʹs first product on the
market.
The Companyʹs technology platform includes an antigen‐discovery system and human antiinfective
monoclonal antibody discovery system, adjuvants and a novel patch‐based delivery
system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has
strategic partnerships with a number of global pharmaceutical companies, including GSK,
Novartis, Merck & Co., Inc., sanofi‐aventis, and Pfizer (formerly Wyeth).
The Companyʹs pipeline of investigational products includes a Travelersʹ Diarrhea Vaccine
Patch (Phase III), a Pseudomonas vaccine candidate (Phase II), a vaccine to prevent Pandemic
Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase II), a
vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III),
as well as a vaccine candidate for Pneumococcus (Phase I). In addition, further products
focused on infectious diseases are in pre‐clinical development.
Intercell is listed on the Vienna stock exchange under the symbol ʺICLLʺ (U.S. level one ADR
symbol ʺINRLYʺ).

Contact Intercell AG
Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Campus Vienna Biocenter 3, A‐1030 Vienna
P: +43‐1‐20620‐1303
LMalfent@intercell.com